Though sales of Lexapro and Namenda won't disintegrate overnight, they will inevitably plunge as cost-conscious medical insurers require patients to switch ...
Lexapro sales remained close to target despite the expected modest decrease in market share and we saw continued solid prescription growth for Namenda, ...
Barron's explains that the pessimism implied by Forest Labs' valuation is explained by a host of expiring patents, most notably FRX's bestseller Lexapro in ...
